Current application of proteomics in biomarker discovery for inflammatory bowel disease

Patrick P. Y. Chan, Valerie C. Wasinger, Rupert W. Leong

Research output: Contribution to journalArticlepeer-review

170 Downloads (Pure)


Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.

Original languageEnglish
Pages (from-to)27-37
Number of pages11
JournalWorld journal of gastrointestinal pathophysiology
Issue number1
Publication statusPublished - 15 Feb 2016
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


  • proteomics
  • inflammatory bowel disease
  • biomarkers
  • molecular diagnostic techniques
  • mass spectrometry


Dive into the research topics of 'Current application of proteomics in biomarker discovery for inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this